title: [Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics].
authors.forename: R
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: E
authors.initials: E
authors.lastname: Francés
authors.forename: R
authors.initials: R
authors.lastname: López-Lizcano
authors.forename: M
authors.initials: M
authors.lastname: Gómez-Maestra
authors.forename: P
authors.initials: P
authors.lastname: Udaondo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000473:pathology*; D008269:Macular Edema / Q000209:etiology / Q000473:pathology*; D011379:Prognosis; D000069579:Ranibizumab; D012008:Recurrence; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000069579:Ranibizumab